Activity from announced rounds
AbbVie Ventures is AbbVie’s corporate venture investment arm. Company and university announcements identify it as an investor in Third Arc Bio and Cloverleaf Bio.
The two companies pursue different therapeutic approaches. Third Arc develops multifunctional antibodies for oncology and immunology; Cloverleaf engineers transfer RNA for cancer treatment. The recorded activity includes Third Arc’s Series A extension and Cloverleaf’s seed financing, linking AbbVie Ventures to both later syndicate support and early company formation.
Cloverleaf Bio is developing engineered transfer RNA therapies that use a modified tRNA payload to inhibit cancer cells' RNA-modifying enzymes. Its lead program targets liver cancer and is advancing toward clinical testing; a second antibody-tRNA program for colorectal cancer remains preclinical.